Renal cell carcinoma: the experience of Kuwait Cancer Control Center, Kuwait

Affiliations

01 January 2005

-

doi: 10.1159/000081914


Abstract

Objectives: This retrospective study was undertaken to analyze the profile of patients presenting with renal cell carcinoma (RCC) and treatment outcomes.

Subjects and methods: Records of 49 patients (36 male, 16 female, 21-75 years) treated at the Kuwait Cancer Control Center, Kuwait for RCC during the period 1993-1998 were analyzed. Forty-one patients had a nephrectomy, 18 postoperative radiotherapy and 1 patient also received adjuvant immunotherapy with interferon. Patients with metastatic disease were treated with a variety of agents including interferon, chemotherapy (vinblastine) or a hormonal agent (megestrol acetate). Data analysis was performed using SPSS statistical software package. Overall survival and disease-free survival were calculated using the Kaplan-Meier method.

Results: Twenty-nine patients presented with symptoms classically associated with RCC. Metastases at diagnosis were seen in 9 patients (18%), with lung being the most frequent site. The commonest tumor subtype was clear cell carcinoma (32.6%). Thirty-nine patients (80%) achieved a complete response to treatment and relapse was documented in 10 patients (26%). The majority of failures were distant, with lung metastases being the most common. Response to salvage treatment was poor. Overall survival was 83% at 2 years. The disease-free survival was 68 and 45% at 2 and 5 years, respectively.

Conclusions: Although many patients presented with advanced local disease, a majority achieved complete response after radical surgery with or without postoperative radiation therapy. Salvage of metastatic disease proved difficult with interferon, chemotherapy.


Similar articles

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.

Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A.Cancer. 2003 Dec 15;98(12):2566-75. doi: 10.1002/cncr.11851.PMID: 14669275

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.J Urol. 2001 Jul;166(1):68-72.PMID: 11435825

Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.

Naitoh J, Kaplan A, Dorey F, Figlin R, Belldegrun A.J Urol. 1999 Jul;162(1):46-50. doi: 10.1097/00005392-199907000-00012.PMID: 10379737

Integration of surgery and systemic therapy for renal cell carcinoma.

Kenney PA, Wood CG.Urol Clin North Am. 2012 May;39(2):211-31, vii. doi: 10.1016/j.ucl.2012.01.005.PMID: 22487764 Review.

Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma.

Geller JI, Dome JS.Cancer. 2004 Oct 1;101(7):1575-83. doi: 10.1002/cncr.20548.PMID: 15378495 Review.


Cited by

Renal primitive malignant tumor with endocrine activity.

Xu N, Jin MS, Chen L, Wang CX, Sun ST, Shi AP.Med Princ Pract. 2013;22(2):200-3. doi: 10.1159/000342194. Epub 2012 Sep 5.PMID: 22964717 Free PMC article.


KMEL References